Advertisement
Advertisement
U.S. markets close in 5 hours 28 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Cue Biopharma, Inc. (CUE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.7150+0.0550 (+2.07%)
As of 10:32AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.6600
Open2.7100
Bid2.7000 x 1000
Ask2.7300 x 1300
Day's Range2.6200 - 2.8450
52 Week Range2.3600 - 18.4200
Volume61,169
Avg. Volume480,988
Market Cap96.036M
Beta (5Y Monthly)1.74
PE Ratio (TTM)N/A
EPS (TTM)-1.4420
Earnings DateAug 15, 2022 - Aug 19, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CUE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cue Biopharma, Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Rating
    Fair Value
    Economic Moat
    last yearMorningstar
View more
Advertisement
Advertisement